[
  {
    "sponsor_name": "BioMarin Pharmaceutical Inc.",
    "candidate_name": "BMN 333",
    "disease_indication": [
      "Multiple growth disorders",
      "Achondroplasia",
      "Hypochondroplasia"
    ],
    "development_phase": "Phase I",
    "moa": "C-type natriuretic peptide (CNP)",
    "route_of_admin": null,
    "status": null,
    "source_url": [
      "[https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGRoKaGZTW3P2euUL3aVTlRMfecYLvODLFHn_Xk24NYV9gmy5gXqIW-IyTFssbf5MkOM8_RgXADPkIlTfvlabAQPfaeMporAMWfr00wocAcPjZnrXm7ah6EkX59XYyq8wJtuuIXHpTBtL7gYgV329reZuTLpn2-jqi0I-4CGBrAX1FzNT2LyQrXDvUzS4Jchh_8KQKVbHyPFYWVeU6VqXzCAGkHd7M]"
    ]
  },
  {
    "sponsor_name": "BioMarin Pharmaceutical Inc.",
    "candidate_name": "BMN 349",
    "disease_indication": [
      "Alpha-1 antitrypsin deficiency (AATD)-associated liver disease"
    ],
    "development_phase": "Phase I",
    "moa": "Alpha-1 Antitrypsin (A1AT) modulator, Protein folding stabilizer, Molecular chaperone",
    "route_of_admin": null,
    "status": null,
    "source_url": [
      "[https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFaIafDSwUqr8yBoPOLQCC8B_p6RomHMOmO6TH4foShho8DnkYTGTI2ol-fwL0W0NkdLz36RocWMSJwfhDG4mjmGV-y1QK7V1lqTDNL4a7Is7fH7F6zOO3sEnwXfzscPj6LslBscKNWzNEoAjEP3TPTiPNbMvT_nr3kwdvSf2NzTnQ_EzOlrVM7GsE-agh-R8b0O-30tsPWO7GimipQQXuMsJXiW9ZOND2YYxdDH0YQtIeuhcw]"
    ]
  },
  {
    "sponsor_name": "BioMarin Pharmaceutical Inc.",
    "candidate_name": "BMN 351",
    "disease_indication": [
      "Duchenne muscular dystrophy (DMD)",
      "DMD with exon 51 skipping amenable genetic mutation"
    ],
    "development_phase": "Phase I",
    "moa": "Antisense oligonucleotide (ASO), DMD exon 51 modulator",
    "route_of_admin": null,
    "status": null,
    "source_url": [
      "[https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHsxgpgNPyLOvsImTafFxjA3lyaXu0HtBMW1YDvbDmJuvWL4pc2YJXk58cTGHTW-jVDx5heJghpwLc0qzVqBKQQobO_LRyCJeLYsl6EJKmP3Rq2M6GQztOnYR9FXkiLRd4KtiTTLrxJUmzOEotpgdevDbHQm0FOYhtAJTemSl-R8VZmLqSHtvwXNnykpVStAcR4AVz5eYtxHUYKYnuUz6i3x-RLA-xw31-hia2lfvUqc6F0o9Xxpe3drx41-q34yAZSqdnGQ1nXyAtGI6mQx5UqqchtssTHESzkvPl2vLGyuybniIwSFPfRMQDnKZ4vKvZ9wZ0LKW5ZmjtRG0nm1-AKV1Na7tU]"
    ]
  },
  {
    "sponsor_name": "BioMarin Pharmaceutical Inc.",
    "candidate_name": "BMN 390",
    "disease_indication": [
      "Phenylketonuria (PKU)"
    ],
    "development_phase": "Preclinical",
    "moa": "Reduces immunogenicity from novel pegylation",
    "route_of_admin": null,
    "status": null,
    "source_url": [
      "[https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHtiT273YeSlEga9SLuxUqPQQ5acuZv7ekpblngHkzUrcrqWohFoktn6sr8nYIlzWvOhJASfarADTEzkjaDZTuFc5SbVNLnxOTVLb5bSx6IyN0s2lQid6OlQX9CkfWbm5kMqgCFMFC7YQkKcxI6iGngNVYjFeGf5l79-5kekUxu6yvHQJ8jdimQZBcgk94KhQ6x3njClBUI-ID9OhsEM9bTOBffYp2LWJSt2SXXI5Fo4Q5KwZBa9FBxr0WZ3MLin7x4LkYapeDovlv-hKzYHkrIteYa_T1RaAKx7L2SkxTB4XE]"
    ]
  },
  {
    "sponsor_name": "BioMarin Pharmaceutical Inc.",
    "candidate_name": "BMN 370",
    "disease_indication": [
      "Von Willebrand Disease (vWD)"
    ],
    "development_phase": "Preclinical",
    "moa": null,
    "route_of_admin": null,
    "status": null,
    "source_url": [
      "[https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHtiT273YeSlEga9SLuxUqPQQ5acuZv7ekpblngHkzUrcrqWohFoktn6sr8nYIlzWvOhJASfarADTEzkjaDZTuFc5SbVNLnxOTVLb5bSx6IyN0s2lQid6OlQX9CkfWbm5kMqgCFMFC7YQkKcxI6iGngNVYjFeGf5l79-5kekUxu6yvHQJ8jdimQZBcgk94KhQ6x3njClBUI-ID9OhsEM9bTOBffYp2LWJSt2SXXI5Fo4Q5KwZBa9FBxr0WZ3MLin7x4LkYapeDovlv-hKzYHkrIteYa_T1RaAKx7L2SkxTB4XE]"
    ]
  },
  {
    "sponsor_name": "BioMarin Pharmaceutical Inc.",
    "candidate_name": "BMN 401",
    "disease_indication": [
      "ENPP1 Deficiency"
    ],
    "development_phase": "Phase II",
    "moa": "First-in-class therapy",
    "route_of_admin": null,
    "status": null,
    "source_url": [
      "[https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGnMBV7OFdYCPjk8EP-1wMRFSbZwchRmQ6zeVutV5dXHJBygfSYuURsHhfa7YrTPR58bJ66dRR-ghlVF_qBjWD4MVFZNIww9A917oipiw0w4lLgsdLu_l4DZM5CsMgsJNS_lsK0FKynZ3vlupVobZaUmUJ5RMn05iTU528VYF1JaXVXsp4C-T_ysox1TnS-NWNwuBfa7jox5INLnteG29UmjJouBYnUaPXFlw1ZCujRFYT059cvpQ==]"
    ]
  },
  {
    "sponsor_name": "BioMarin Pharmaceutical Inc.",
    "candidate_name": "BMN 293",
    "disease_indication": [
      "Myosin binding protein C3 (MYBPC3) hypertrophic cardiomyopathy"
    ],
    "development_phase": "Preclinical",
    "moa": "AAV gene therapy, restores cardiac MYBPC3 expression",
    "route_of_admin": null,
    "status": null,
    "source_url": [
      "[https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHixC7Bh7by6XkwvdzF36K2Cerc0vV-cu7LOZeYVfR8Hxum6J7gFXrkKxD1wPbvxQH1Q3CZ9gNScw7yezFVzZt9MquqAfdUR-oRzSz3E_iFgjbFBHmsfJGWe2BofpMHdBjExgYapsbp6VPLUQ4oTvVVMl9qP44cIbAIMMA1CFT-dU9z4h9LkNHby8S-6rgXKNsT6Efyg5A=]"
    ]
  },
  {
    "sponsor_name": "BioMarin Pharmaceutical Inc.",
    "candidate_name": "BMN 331",
    "disease_indication": [
      "Hereditary angioedema (HAE)"
    ],
    "development_phase": "Phase I",
    "moa": "AAV5-mediated gene therapy, C1-INH stimulants, AAV5 hSERPING1 (wild-type human C1 Esterase Inhibitor)",
    "route_of_admin": null,
    "status": null,
    "source_url": [
      "[https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGRoKaGZTW3P2euUL3aVTlRMfecYLvODLFHn_Xk24NYV9gmy5gXqIW-IyTFssbf5MkOM8_RgXADPkIlTfvlabAQPfaeMporAMWfr00wocAcPjZnrXm7ah6EkX59XYyq8wJtuuIXHpTBtL7gYgV329reZuTLpn2-jqi0I-4CGBrAX1FzNT2LyQrXDvUzS4Jchh_8KQKVbHyPFYWVeU6VqXzCAGkHd7M]"
    ]
  },
  {
    "sponsor_name": "BioMarin Pharmaceutical Inc.",
    "candidate_name": "BMN 255",
    "disease_indication": [
      "Metabolic dysfunction-associated steatohepatitis (MASH)",
      "Non-alcoholic fatty liver disease (NAFLD) and hyperoxaluria",
      "Hyperoxaluria in chronic liver disease"
    ],
    "development_phase": "Phase I",
    "moa": null,
    "route_of_admin": null,
    "status": null,
    "source_url": [
      "[https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHBvaOjsoI0AY-SOdtF6o3CrbYXGJZ8PYHEikILKJVGydf8DF86XOXB20Y1YrQ6sBP2_4AP2o-2il6_S1OMvKwCF2H_Lc3xsyhtJhvCy6A_J2c4Lfr0tzxKfh5XDX4dxPCIwIrKWJBbD6_PK4HAWNPdrdAW8eloh2O4H2yq]"
    ]
  },
  {
    "sponsor_name": "BioMarin Pharmaceutical Inc.",
    "candidate_name": "BMN 355",
    "disease_indication": [
      "Long-QT syndrome types 2 and 3"
    ],
    "development_phase": "Preclinical",
    "moa": "Monoclonal antibody, selectively increases Kv7.1 ion channel activity",
    "route_of_admin": null,
    "status": null,
    "source_url": [
      "[https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGRoKaGZTW3P2euUL3aVTlRMfecYLvODLFHn_Xk24NYV9gmy5gXqIW-IyTFssbf5MkOM8_RgXADPkIlTfvlabAQPfaeMporAMWfr00wocAcPjZnrXm7ah6EkX59XYyq8wJtuuIXHpTBtL7gYgV329reZuTLpn2-jqi0I-4CGBrAX1FzNT2LyQrXDvUzS4Jchh_8KQKVbHyPFYWVeU6VqXzCAGkHd7M]"
    ]
  },
  {
    "sponsor_name": "BioMarin Pharmaceutical Inc.",
    "candidate_name": "BMN 365",
    "disease_indication": [
      "Plakophilin-2 (PKP2) mutations and arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C)"
    ],
    "development_phase": "Preclinical",
    "moa": "AAV gene therapy, replacement gene to form a protein",
    "route_of_admin": null,
    "status": null,
    "source_url": [
      "[https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGRoKaGZTW3P2euUL3aVTlRMfecYLvODLFHn_Xk24NYV9gmy5gXqIW-IyTFssbf5MkOM8_RgXADPkIlTfvlabAQPfaeMporAMWfr00wocAcPjZnrXm7ah6EkX59XYyq8wJtuuIXHpTBtL7gYgV329reZuTLpn2-jqi0I-4CGBrAX1FzNT2LyQrXDvUzS4Jchh_8KQKVbHyPFYWVeU6VqXzCAGkHd7M]"
    ]
  }
]